Royalty Report: Medical, Device, Surgical – Collection: 7335

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Medical
  • Device
  • Surgical
  • Delivery
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7335

License Grant
Assignor hereby assigns, and transfers unto Hong Kong Assignee The entire right, title and interest in the Patent Properties and in the corresponding inventions and in all subsequent divisions and continuations, or reissues or extensions thereof and in all patents issuing thereon in the United States or foreign countries, and in all corresponding patent applications filed in countries foreign to the United States, and in all patents issuing thereon in said foreign countries.

The right to file foreign patent applications on said invention in its own name, wherever such right may be legally exercised, including the right to claim the benefits of the International Convention for such applications.

License Property
7798MYl/PM/IAN/tam, Bandage based pain control through the delivery of electric impulses to the body.

IPSCIO Record ID: 28651

License Grant
Assignors, two individuals, hereby sell, assign, and transfer exclusively and subject to all of the terms and conditions of this Agreement, their entire right, title, and interest in and to the Device and the Intellectual Property.
License Property
“Applications” shall mean any and all pending patent applications filed by Assignors relating to the Device and any apparatus and/or method for reducing, sizing and/or stabilizing the circumference of a vascular or anatomical structure designed or used by Assignors, including, but not limited to, the following
(a) In the United States, application No. 09/733,224 entitled Annuloplasty System, filed December 8, 2000;
(b) In Canada, application No. 2,197,069 entitled Apparatus for Reducing the Circumference of a Vascular Structure, filed August 10, 1995;
(c) In the European Region, application No. 95929486.9 entitled Apparatus for Reducing the Circumference of a Vascular Structure, filed August 10, 1995; and
(d) In Japan, application No. 507532/1996 entitled Apparatus for Reducing Circumference of Vascular Structure, filed August 10, 1995 and any and all patents and/or patent applications claiming priority thereto, and any and all patents or patent applications in which either Segmed or Dr. Northrup is an inventor, which relate to the Device and/or any apparatus and/or method for reducing, sizing and/or stabilizing the circumference of a vascular or anatomical structure, and any reissues, continuations, divisions, continuations-in-part or extensions thereof, any patents issuing therefrom; and/or any improvements thereto or enhancements thereof which are either wholly or in part owned, invented, controlled, acquired or otherwise assignable by either or both of the Assignors, and any patent applications therefor and any patents issuing therefrom.

“Device” shall mean the apparatus and/or method for reducing, sizing and/or stabilizing the circumference of a vascular or anatomical structure (the “Field”) covered by the Intellectual Property and fully described in the Applications and applications relating to the Patents, and any and all improvements, modifications, derivations, enhancements, technology, Know-how and Documentation related thereto.

Patent relates to a new annuloplasty technology for the repair of mitral and tricuspid heart valves.

“Patents” shall mean the following patents issued to Assignors in the United States, Australia, Taiwan and South Africa
(a) In the United States, U.S. Patent No. 5,593,424 entitled Apparatus and Method for Reducing and Stabilizing the Circumference of a Vascular Structure, issued January 14, 1997, U.S. Patent No. 5,709,695 entitled Apparatus for Reducing the Circumference of a Vascular Structure, issued January 20, 1998, and U.S. Patent No. 5,961,539 entitled Method and Apparatus for Sizing, Stabilizing and/or Reducing the Circumference of an Anatomical Structure, issued October 5, 1999;
(b) In Australia, patent No. 700530 entitled Apparatus for Reducing Circumference of Vascular Structure, filed August 10, 1995;
(c) In Taiwan, patent No. 096871 entitled Apparatus for Reducing the Circumference of a Bodily Structure, filed August 11, 1995; and
(d) In South Africa patent No. 95/6672 entitled Apparatus and Method for Reducing the Circumference of a Vascular Structure, filed August 10, 1995,
and any and all patents and/or patent applications claiming priority thereto, and any and all patents or patent applications in which Assignors are an inventor, which relate to the Device and/or any apparatus or method for reducing, sizing and/or stabilizing the circumference of a vascular or anatomical structure, and any reissues, continuations, divisions, continuations-in-part or extensions thereof, any patents issuing therefrom, and/or any improvements thereto or enhancements thereof which are either wholly or in part owned, invented, controlled, acquired or otherwise assignable by Assignors, and any patent applications therefor and any patents issuing therefrom.

“Trademark” shall mean the mark represented by United States Registration No. 2,108,883 for the “SEGMENT” mark.

IPSCIO Record ID: 25890

License Grant
The Licensor assigned the patent rights relating to International Patent Application No. PCT/IB2012/001470 to the Licensee of in Hong Kong.  Licensor is the beneficial stockholder of Licensee.
License Property
International Patent Application No. PCT/IB2012/001470 entitled Pain Management Device.

IPSCIO Record ID: 352092

License Grant
Assignor assigned its entire right, title, and interest in the Innovation to Assignee.

To the extent Assignee grants a license of the Innovation, or any part thereof, to any third party, and receives Revenue therefrom, then Assignee agrees to pay to Assignor a percentage of Revenue received in the aggregate by Assignee from all such licensees granting rights to the Innovation, distributed by Assignee.

License Property
Assignor assigned its entire right, title, and interest in the Assigned Patent Applications, inventions and improvements therein, and Letters Patent (referred to herein collectively as the “Innovation”) to Assignee via that certain Assignment  recorded with the United States Patent and Trademark Office on November 16, 2016 at reel and frame number 040337/0243.
Field of Use
Field of use is for the medical industry.

Assignee is a developer of rapid health information technologies.

IPSCIO Record ID: 115864

License Grant
The University grants to the Licensee a worldwide license under Licensors Patent Rights to make, have made, use, sell, and distribute Licensed Products and to practice Licensed Method.  The Licensor also grants to the Licensee the right to issue sublicenses to third parties to make, have made, use, sell, and distribute Licensed Products and to practice the Licensed Method.
License Property
The license is for certain inventions, generally characterized as a noninvasive continuous iontophoretic blood monitor/drug delivery system.  Patents relates to devices for iontophoretic non-invasive sampling of substances.

The Licensed Product is any material that is either covered by Licensor’s Patent Rights or any product manufactured using the Licensed Method, in either event to the extent the manufacture, use or sale of which in a particular country infringes an unexpired valid claim of a patent or a pending claim of a patent application under Patent Rights in that country in which such patent has issued or application is pending.

The Licensed Method is any method that is covered by the claims of Licensor’s Patent Rights in the country in which such method is used, or the use or practice of which would constitute, but for the license granted to the Licensee pursuant to this Agreement, an infringement of any unexpired, valid issued claim or pending claim under Patent Rights in that country in which the Licensed Method is used or practiced.

(a) U.S. Patent Application serial no. 150,159, filed 29 Jan 88,(abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;

(b) U.S. Patent Application serial no. 299,397, filed 24 Jan 89, as a continuation-in-part application of (a), (abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;

(c) U.S. Patent Application serial no. 771,483, filed 04 Oct 91, as a continuation-in-part of (b) (now allowed) by Dr. Richard Guy, et al., and assigned to The Regents;

(d) U.S. Patent No. 5,279,543, issued 18 Jan 94, which was a file wrapper continuation application of (b), by Dr. Richard Guy, et al, and assigned to The Regents; and continuing applications thereof including divisions and substitutions but including continuation-in-part applications only to the extent that the claim was supported in the original disclosure; any patents issuing on said application or continuing applications including reissues and extensions; and any corresponding foreign applications or patents.

Field of Use
This agreement pertains to drug delivery systems.  The Licensee, GlucoWatch system is designed to measure glucose frequently, automatically and non-invasively through the ease and convenience of a device worn like a wristwatch.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.